Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy

Advanced melanoma remains a disease with poor prognosis. Several serologic markers have been investigated to help monitoring and prognostication, but to date only lactate dehydrogenase (LDH) has been validated as a standard prognostic factor biomarker for this disease by the American Joint Committee...

Descripción completa

Detalles Bibliográficos
Autores principales: Irurzun-Arana, Itziar, Asín-Prieto, Eduardo, Martín-Algarra, Salvador, Trocóniz, Iñaki F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198615/
https://www.ncbi.nlm.nih.gov/pubmed/32366871
http://dx.doi.org/10.1038/s41598-020-63441-6